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Assessment of Endothelial Cell Dysfunction in Pregnant Women with 
either Preeclampsia or Preexisting Vascular Disease by Brachial Artery 
Ultrasound. 
Inna Landres (1), Maria Small (1), Adesh Surjusingh (2), Samuel Ramsawak (2) Keith P. 
Williams (3). Department of Obstetrics and Gynecology, Yale University School of 
Medicine, New Haven, CT (1), Department of Obstetrics and Gynecology, Mount Hope 
Maternity Hospital, University of the West Indies, Port of Spain, Trinidad (2), 
Department of Obstetrics and Gynecology, Hospital of St. Raphael, New Haven, CT (3). 
The purpose of this research was to investigate vascular dysfunction in pregnant 
women with either preeclampsia or preexisting vascular disease using non-invasive 
brachial artery ultrasound. 
The first study is a matched case control of 12 preeclamptic vs. 24 normotensive 
pregnant women. The second study is a prospective cohort of 40 pregnant women with 
preexisting vascular disease (Diabetes, Chronic Hypertension, Thromboembolic disease, 
or previous Preeclampsia). This group represents women at high risk for developing 
preeclampsia. 
Main outcome measurements were brachial artery flow mediated vascular dilation 
(FMVD) and doppler waveform analysis. In the prospective cohort, additional outcome 
measurements included the development of preeclampsia, the severity of disease and 
adverse maternal and fetal outcomes. 
Brachial Artery flow mediated vascular dilation (FMVD) was significantly 
reduced in women with preeclampsia (4.5% ± 2.7%) compared with matched controls 
(9.8% ± 4.0%); p< 0.002. The timing of maximum dilation was variable among subjects 
and represents the best measurement of the difference in FMVD between the two groups. 
Correlation analysis between the change in Doppler waveform parameters (acceleration, 
acceleration time, peak systolic velocity and pulsatility index) and change in FMVD 
identified only peak systolic velocity (PSV) as significant; p=0.040. However, 

comparison of change in PSV between preeclamptic and normotensive controls was not 
significant (13.5% ± 22.7%, vs. 20.5% ± 27.8%); p=0.432. 
In summary, endothelial function is impaired in women with preeclampsia as well as in 
women with preexisting vascular disease who are at high risk for developing 
preeclampsia. These findings support the central role of endothelial dysfunction in the 
pathogenesis of preeclampsia. Brachial artery sonography is a useful non-invasive 
method of detecting endothelial dysfunction in pregnant women and may have a role in 
predicting the development of preeclampsia in high risk groups. 
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INTRODUCTION 
A. Preeclampsia: Definition and Dilemmas 
Preeclampsia is defined as new onset of hypertension and proteinuria 1 after 20 
weeks of gestation (1). It is a common complication of pregnancy, affecting between 3 to 
14% of pregnancies worldwide and about 5 to 8% pregnancies in the United States, and is 
associated with significant maternal and fetal morbidity (2). In a recent review of 335 
patients with preeclampsia, 51 (17%) developed thrombocytopenia with 26 (8%) 
developing the full HELLP syndrome (Hemolysis, Elevated Liver Enzymes and Low 
Platelets). Twenty-two patients (7.3%) had DIC, with placental abruption occurring in 10 
of these patients. Seven patients developed pulmonary edema, 5 developed cerebral 
complications and 3 developed acute renal failure (3). One of the most feared 
complications of preeclampsia, is progression to eclampsia, generalized seizures, 
resulting in very high maternal and fetal mortality. The rates of eclampsia vary 
significantly depending on the severity of preeclampsia (from 0.5% in mild disease to 2% 
in severe preeclampsia), use of magnesium prophylaxis and patient demographics (4). 
Fetal complications of preeclampsia include premature delivery, low birth weight, intra¬ 
uterine growth restriction and fetal demise. 
Preeclampsia is currently the third leading cause of maternal death in the United 
States (5). With such a high incidence of severe maternal and fetal complications of 
preeclampsia it is important to determine early predictors of this disease. Preeclampsia is 
an evolving dynamic process associated with progressive and generalized vasospasm and 
1 Hypertension is defined as either >140 mmHg systolic or >90 mmHg diastolic. Proteinuria is defined as 
> 300mg in a 24 hour urine specimen collection and is suggested (but not diagnostic) by a random urine 
protein of 30mg/dl or 1+ protein on urine dipstick. 
■ 
' 
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inconsistent involvement of organs including kidney, liver, brain and the hematological 
system. Women at higher risk for developing preeclampsia include primigravidas, 
women with multiple pregnancies, and women with a strong family history of 
preeclampsia. Many preexisting medical conditions predispose women to preeclampsia 
including diabetes, obesity, chronic hypertension, vascular and connective tissue disease, 
thrombophilia and previous preeclampsia. However, although certain patients are at 
higher risk for developing preeclampsia, currently there is no way to predict who will go 
on to have the disease. The pathogenesis of preeclampsia, while extensively studied, is 
not entirely understood. Without a good understanding of the pathogenesis as well as 
early predictors of preeclampsia it is difficult to focus on preventive strategies. 
B. Preeclampsia: Pathogenesis 
The pathogenesis of preeclampsia is yet to be fully understood. It is thought to 
result from both fetal and maternal factors. In preeclamptic women, there is impairment 
in trophoblast differentiation and invasion into maternal arteries leading to placental 
ischemia and release of products causing maternal endothelial cell dysfunction. The 
primary event that contributes to failed trophoblast differentiation is unknown, but 
placental ischemia, immunologic factors, and genetic factors are thought to play a role 
(6). It is unclear if the ischemic placenta is the cause or consequence of abnormal 
trophoblast invasion. Pre-existing maternal impaired endothelial function is believed to 
contribute to the pathogenesis of preeclampsia. 
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C. Endothelial Dysfunction 
Regardless of the initiating factors, endothelial cell dysfunction is the final 
common pathway in the pathogenesis of preeclampsia. The endothelial-dependent 
response to stress is principally regulated by the release of Nitric Oxide (NO), resulting in 
dilation. This endothelium-dependent response to stress is called flow-mediated vascular 
dilation (FMVD). An abnormality in the role of NO has been proposed as the main 
mechanism underling endothelial dysfunction observed in preeclampsia (7, 8). Recently, 
it has been shown that the likely mechanism for reduced endothelial NO activity in 
preeclampsia is reduced action of endothelial NO rather than decrease in production (9). 
Impaired FMVD has been demonstrated in a number of conditions affecting the 
endothelium, including atherosclerosis, hypertriglyceridemia, hyperinsulinemia, obesity 
and a history smoking (10). 
Several medical disorders which uniquely promote endothelial cell dysfunction 
have been associated with a significantly elevated risk of preeclampsia. These include 
chronic hypertension, diabetes, thrombophila, vascular and connective tissue disease and 
obesity (11). Endothelial cell changes and resulting dysfunction is thought to occur early 
in the pregnancy, before the clinical expression of the disease as hypertension and 
proteinuria. To date, the best in vivo test of endothelial dysfunction has not been 
identified and applied early in a high-risk population to predict the development of 
preeclampsia. 
D. Brachial Artery Ultrasound to measure Endothelial Dysfunction 
: 
■ .( 
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Brachial artery ultrasound imaging during reactive hyperemia is a tool used 
widely for establishing the presence of endothelial dysfunction and has a potential role as 
a screening tool for coronary artery disease (12, 13). This technique provokes the release 
of NO, resulting in FMVD that can be quantified using high-frequency ultrasound. Many 
studies in non-pregnant patients with atherosclerosis and diabetes have identified 
impaired brachial artery reactivity (defined as a significant reduction in FMVD) which 
correlated with increasing endothelial cell dysfunction. This non-invasive method of 
endothelial dysfunction assessment has been shown to be both reproducible and accurate 
(14). A number of protocols and guidelines exist in the literature describing optimal 
assessment of endothelial dependent FMVD of the brachial artery (14, 15, 16, 17). 
E. Previous Work in Brachial Artery Ultrasound and Pregnant Women 
Very few studies have applied brachial artery reactivity as a measure of 
endothelial dysfunction in pregnant patients. Dorup et al., described the pattern of 
brachial artery reactivity in normal pregnancy (18). A significant increase in FMVD was 
noted for all trimesters, reaching the highest value in the third trimester (7.2% ± 2.8% for 
non-pregnant controls vs. 9.1% ± 4.0% for first trimester, 9.1% ± 3.7% for second 
trimester and 10.6% ± 4.4% in the third trimester). Sawiddou et al., identified a 
significant reduction in FMVD in 37 insulin requiring diabetic pregnant women at 20 
weeks’ gestation compared to healthy pregnant controls (6.43% ± 3.66% vs. 9.43% ± 
3.69%, p<0.001) (19). 
There are two studies that specifically examined flow mediated vascular dilatation 
of the brachial artery in preeclamptic women. In a case-control study of 99 pregnant 
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women, including IUGR, mild and severe preeclampsia as well as normal controls, 
Takata et al., noted decrease in FMVD of the brachial artery for both mild and severe 
preeclamptic group versus controls (2.3% ± 3.7% vs. 1.6% ± 3.8% vs. 5.0% ± 3.2%; 
p<0.05) but not in the IUGR group (5.2% ± 3.1%). However, the protocol used in this 
study differed from standard protocols for inducing hyperemia and thus the results may 
not carry external validity (20). Another smaller case-control study by Kuscu et al., 
demonstrated a significant difference in FMVD between 15 preeclamptic and 11 
normotensive women (4.26%, SEM 0.69% vs. 12.18%, SEM 1.97%; p=0.001) (21). The 
authors repeated measurement in the preeclamptic group at 2 and 6 weeks' post-partum 
and found a gradual increase in FMVD (6.67%, SEM 0.89% at 2 weeks’ post-partum and 
9.27%, SEM 1.16% at 6 weeks). 
These studies both demonstrate a significant reduction in FMVD in preeclamptic 
women signifying impaired vascular reactivity. However, they do not elucidate the 
timing or duration of endothelial dysfunction. To clarify the role of maternal endothelial 
dysfunction in preeclampsia, Chambers et al., have examined brachial artery FMVD in 
women with a history of preeclampsia, at least 3 years postpartum (n=l 13). Interestingly, 
there was a significant decrease in FMVD compared with controls and the impairment of 
endothelial function was more severe in women with recurrent preeclampsia (0.9% ± 
4.1% for recurrent group, 2.7% ± 3.5% for single episode group vs. 4.7% ± 4.3% in 
controls, p<0.001) (22). The authors hypothesize that their findings imply that “the 
bioavailability of endothelial nitric oxide may be reduced in preeclamptic women, even 
in the nonpregnant state”. Their argument is further supported by transient reversal of 
impairment in FMVD in 15 women with previous preeclampsia, but not in normal 

controls, by ascorbic acid, a powerful antioxidant. (2.6% ± 3.3% pre treatment, 5.6% 
±3.0% post treatment, p=0.001). 
Recently, two studies have demonstrated a significant decrease in FMVD in 
pregnant women who subsequently develop preeclampsia. The first study, by Sawidou 
et al., assessed brachial artery reactivity in a cohort of 86 women at 23-25 weeks 
gestation. FMVD in women who eventually developed preeclampsia (n=10) was 
significantly reduced (3.58% ± 2.76% vs. 8.59% ± 2.76; p<0.0001) (23). This 
impairment predated the development or preeclampsia symptoms by at least 10 weeks 
and the impairment was as great as that observed in non-pregnant patients with 
cardiovascular risk factors for endothelial dysfunction. The second study, by Takase et 
al., examined a cohort of 43 pregnant women at high-risk for preeclampsia in the second 
half of their pregnancy and also demonstrated a significant reduction in FMVD in women 
who developed preeclampsia, (1.6% ± 1.0% vs. 11.0% ± 4.5%, p<0.05). By additionally 
examining 14 non-pregnant age-matched controls and obtaining a normal cut-off value of 
3%, the authors determined the positive predictive value for development of subsequent 
preeclampsia is 90% and the negative predictive value is 100% (24). 
F. Limitations of previous work 
The limited study of brachial artery reactivity in pregnant patients support the 
hypothesis that endothelial cell dysfunction in preeclampsia is demonstrated by brachial 
artery FMVD changes. Furthermore, endothelial cell dysfunction can be documented 
using non-invasive brachial artery ultrasound prior to the onset of preeclamptic 
symptoms. However, a number of limitations exist among previous work of brachial 
- • 
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artery reactivity in pregnant women. There are few studies using brachial artery 
ultrasound in pregnant women and, among existing studies, there is variability in protocol 
as well as outcome measurements of FMVD. The majority of the studies are cross- 
sectional case-controls with limited outcome data available. Most of the studies assess 
only brachial artery diameter parameters. The few that measure Doppler waveforms have 
had inconsistent results. Diabetics have been the only group of patients with preexisting 
vascular dysfunction examined during pregnancy. There have been no assessments of 
brachial artery reactivity in asymptomatic patients with specific high risk factors for 
preeclampsia, including diabetes, chronic hypertension and thromboembolic disease. 
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HYPOTHESIS AND SPECIFIC AIMS 
Our hypothesis is that there are significant differences in flow mediated vascular 
dilation (FMVD) as well as Doppler waveforms in the brachial artery between 
preeclamptic and normotensive women and that these differences are present prior to the 
development of symptomatic preeclampsia. 
Primary Specific Aim: 
1) To compare vascular changes in the brachial artery between preeclamptic and 
normotensive women by measuring FMVD, an assessment of endothelial cell 
dysfunction. 
Secondary Specific Aims: 
2) To determine the gold-standard for measuring changes in brachial artery diameter 
among pregnant patients by assessing the time course of the hyperemic response 
and determining the maximum end-diastolic dilation. 
3) To examine the utility of Doppler waveform analysis of the brachial artery and 
compare the Doppler waveforms and FMVD measurements in preeclamptic and 
normotensive women. 
4) To investigate the role of Brachial Artery Ultrasound in predicting the 
development of Preeclampsia and to assess the role of maternal vascular 
dysfunction, as identified by brachial artery ultrasound, in determining pregnancy 
outcomes. 

METHODS 
A. Participant Recruitment 
I. Study setting and recruitment 
The study was conducted at two geographic settings and three hospitals: (1) Yale- 
New Haven Hospital (YNHH) in New Haven, CT, (2) Mount Hope Maternity and (3) 
Port of Spain General Hospital in Port of Spain, Trinidad. All three hospitals were 
affiliated with a University academic center. In Trinidad, we were working in 
collaboration with the Obstetrics and Gynecology Department of the University of the 
West Indies. 
The study was advertised in the perinatal unit of YNHH as well as the obstetrical 
clinics of Mount Hope Maternity (see APPENDIX A for advertisement content). To 
identify potential participants for either the high risk cohort or preeclampsia group at 
YNHH, we worked closely with Candice Kohn, the Case Coordinator at YNHH, Nancy 
Nichols, the Diabetes Nurse, as well as attendings, fellows, residents and staff of the high 
risk service. Potential participants were approached either during their High Risk Clinic 
appointment or, if inpatient, on the wards. Interested participants were given a brochure 
describing the study in more detail followed by a five minute explanation of study 
components, including informed consent. The study time was arranged based on 
convenience to the patient; either at a later time or directly following recruitment. The 
study was conducted either at the YNHH Perinatal Unit or directly in the patient room for 
inpatients. 
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To recruit potential participants in Trinidad we worked closely with the attendings 
and residents at the obstetrical clinics and wards of Mount Hope Maternity as well as the 
inpatient staff at Port of Spain General Hospital. Port of Spain General Hospital has a 
separate inpatient ward consisting of 8 beds for patients with preeclampsia or gestational 
hypertension. In the clinics, a separate room was dedicated to the brachial ultrasound 
study, while on the wards the study was conducted at the bedside of the patient. 
Participation in the study was strictly voluntary and under no circumstance 
interfered with the care of the patient. Participants were allowed to withdraw at any point 
during or after the study. Participants from YNHH did not receive any compensation for 
the study while participants from Trinidad received a small baby gift (<$5 US in value) 
as a token of our appreciation. 
The criteria for inclusion in the Case Control Study were the following (1) 
Gestational Age > 20 weeks, and either a (2) confirmed diagnosis of preeclampsia using 
standard clinical criteria or (3) normotensive, low-risk pregnancy with no previous 
history of preeclampsia, hypertension, PIH, or diabetes. 
For the High-Risk Cohort study we recruited patients with one or more of the 
following risk factors for endothelial dysfunction and preeclampsia: 
(1) Chronic Hypertension - documented blood pressure of > 140/90 and prior to 
pregnancy. 
(2) Diabetes - either pre-gestational or requiring gestational diabetics (DMA2). For 
patients with DMA2, additional risk factors such as obesity were required. 
(3) Previous preeclampsia/eclampsia - documented during one of previous 
pregnancies. 
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(4) Gestational Hypertension (PIH) - hypertension developing during the current 
pregnancy without new onset proteinuria. 
(5) Thromboembolic disease - Documented DVT or PE during this or prior 
pregnancy unrelated to trauma, or known thrombophilia with appropriate high 
risk factors. 
All women were taking prenatal vitamins. Nine out of 21 women with chronic or 
gestational hypertension were taking anti-hypertensive medications at the time of study: 
lobetalol (5), nifedipine (3), and methyldopa (2). Additional medications in the high risk 
cohort included albuterol (5), folic acid (2), paroxetene (1) and oxycodone (1). None of 
the above mentioned medications have known direct effects on endothelial function. 
Exclusion Criteria for both of the studies were (1) age <18 (2) timing of smoking 
< 4 hours prior to the study (3) Multiple pregnancy (4) preexisting kidney disease (5) 
carpal tunnel syndrome or other arm/hand disabilities and (6) medications that have the 
potential to interfere with endothelial function, such as nitrates (specifically, Isosorbide 
Dinitrite or nitroglycerin), antioxidants (Vitamins C and E) or aspirin. 
II. HIC approval 
HIC protocol approval was obtained prior to the initiation of the study by Dr. 
Williams on March 3, 2001 (HIC#12188) and amended to include myself as an 
investigator on August 15, 2003. The protocol was renewed by HIC on March 24, 2004 
for 1 year. Approval for conduction of the study in Trinidad was obtained from the 
Internal Review Board of each of the hospitals and the HIC protocol was reviewed by 
sponsoring members of each hospital administration. 
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III. Informed Consent 
In accordance with the HIC protocol, all participants of the study at YNHH were 
given full written disclosure of the project, explaining the procedure, risks, benefits, 
voluntary participation and withdrawal as well as assurance of confidentiality. They 
were asked to read and sign two forms (1) Consent for Participation in a Research Project 
Yale University School of Medicine- Yale-New Haven Hospital (2) Research 
Authorization (use and disclosure of personal information). The two forms were 
reviewed with each participant and all questions were answered prior to signature. 
Participants of the study at Mount Hope Maternity and Port of Spain General hospitals 
were given oral disclosure of the project in addition to a brief written explanation of the 
procedure, risks, benefits, confidentiality and voluntary participation. Oral consent was 
obtained from all participants in accordance with the Internal Review Board of the 
hospitals as is customary for research participants in non-invasive studies in Trinidad. 
IV. Sample Size 
Estimations of sample size for our primary aim were calculated using computer 
software available online . We used values from literature to estimate sample size 
needed with a 2:1 ratio of controls to preeclamptics for our matched case control study. 
Assuming a power of 90% and significance at 5% (a=0.05), we would need between 7-10 
preeclamptic women (difference in n reflects variation of values from literature) and 14- 
20 controls. 
2 UCLA Department of Statistics, calculators.stat. ucla. edu/powercalc/ 
University of Iowa Department of Statistics: www.virtualstatistician.com 
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V. Ethical Considerations 
As part of the data collection, we needed to include personal information about 
each patient such as age, ethnicity, parity, and medical history. Participants were assured 
the confidentiality of all personal data. Patient status was discussed with medical staff 
only under strict confidentiality. None of the data or results of the study were shared 
with the medical staff taking care of the patients. To ensure privacy, codes were 
substituted for identifiers in all analyses. 
The risks to participants in this study were minimal. The brachial artery 
ultrasound is a non-invasive test. There is mild discomfort experienced during forearm 
brachial artery occlusion with a blood pressure cuff and all subjects were carefully 
monitored during the procedure to minimize any discomfort. 
Under the condition of the study, we are not able to reveal to the patient or her 
provider the results of the study until all outcomes are collected. Since currently there are 
no effective prevention protocols available for Preeclampsia, it would not benefit the 
patient to know her risk of developing preeclampsia. 
B. Ultrasound Assessment of the Brachial Artery 
I was responsible for performing all ultrasound measurements and analysis at both 
YNHH and Trinidad (see section V, technique training for more details). 
I. Equipment 
All Brachial Artery scans were done using the Logiq book portable ultrasound 
machine with a 7MHz linear array transducer (both from GE Healthcare). A standard, 
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manual sphygmomanometer with a regular cuff size was used for forearm occlusion of 
the brachial artery at the patient’s forearm (see Protocol) as well as for blood pressure 
measurement (using large cuff size when necessary). Data were saved as JPEG, AVI and 
DICOM files and were transferred from the ultrasound machine to a personal computer. 
All data and analysis were stored and saved on an IBM laptop personal computer with an 
encrypted password as well as on separate CD-R’s that were kept in a secure cabinet. 
II. Protocol 
The following established protocol was developed from review of current literature as 
well as a pilot study of non-pregnant subjects (N=10). 
1) Patient position 
Each patient is placed in a quiet, temperature-controlled room (22-26°C) in either the 
supine or left lateral position for 10 minutes prior to the ultrasound exam. 
A manual sphygmomanometer is placed on the forearm of the patient. 
2) Baseline Diameter measurement 
The right brachial artery is scanned over a longitudinal section 2-15cm above the elbow 
to locate the clearest image of the artery lumen. The longitudinal diameter of the brachial 
artery is measured from high-resolution B-mode image obtained with a 7MHz linear 
array transducer. The depth and gain controls are set to optimize visualization of the 
lumen to arterial wall interfaces. A 30 second recording of the brachial artery is obtained 
to measure baseline diameter. 
3) Flow-restriction induction 
Flow-mediated dilation is assessed by measuring the post-ischemic changes in the 
diameter of the brachial artery (the hyperemic state). To create the hyperemic state, the 
1 
' 
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sphygmomanometer is inflated to a pressure of 250-300mmHg. The pressure is held 
above 250mmHg for 5 minutes. If the subject experiences discomfort, the pressure is 
lowered but held at a minimum of >50mmHg above the systolic blood pressure (taken 
prior to the experiment). After 5 minutes, the blood pressure cuff is rapidly released to 
zero. 
4) Flow-mediated dilation recording 
The brachial artery is imaged continually using the color-flow mode from the point of 
cuff deflation (t=0) to 90 seconds, and again at 120 seconds. 
5) Doppler Waveforms 
Doppler flow velocity recordings are taken before cuff inflation (baseline) and again at 
90 seconds after cuff deflation for duration of at least 3 cardiac cycles. The flow velocity 
was taken from the center of the brachial artery with the Doppler set parallel to artery 
lumen. 
III. Image storage and measurements of vessel diameter 
All images were recorded and stored on both the ultrasound machine HD and CD- 
Rom for later analysis. Data were saved as JPEG, AVI and DICOM files. Images were 
saved as a single folder with the assigned subject identification number and were not 
linked to any identifying data. Measurements were taken at a later point, with the 
investigator blinded to subject identification. 
Measurements of the vessel diameter were taken from the leading edge of the 
anterior wall to the leading edge of the posterior wall of the brachial artery at the end of 
diastole (See Figure 1). Each measurement was recorded as the mean of 3 different 
points along the length of at least 0.8cm of lumen wall. The baseline (resting) vessel 
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diameter was calculated as a mean of two measurements between 0-30 seconds of 
recording. The measurements of flow-mediated hyperemic response were calculated 
between 10 and 90 seconds at 15 second intervals and again at 120 seconds for a total of 
7 post-cuff release measurements. 
Changes in diameter at each time point were calculated as percentage change 
relative to the resting diameter (%FMVD): 
% FMVD = (Vessel diameter after cuff deflation - Baseline diameter) X 100 
at x seconds Baseline diameter 
The timing of Maximum FMVD (Tmax) was determined from the seven measurements 
between 10 and 120 seconds. If maximum FMVD was equal at two different time points, 
the average time between the two time points was assigned, (ex: FMVD=8.5% at both 50 
seconds and 70 seconds; FMVDmax recorded as 8.5% at Tmax = 60 seconds.) 
FIGURE 1. Sample measurement of Flow Mediated Vascular Dilation (FMVD) 
A. Example of Baseline diameter measurement 
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Fig 1. A sample measurement of brachial artery diameter at (A) baseline and (B) 40 
seconds post cuff deflation. Each measurement is recorded as the mean of 3 different 
points along the length of the lumen wall. Calculation of the Flow Mediated Vascular 
Dilation (FMVD) is illustrated on the right. 
IV. Doppler Waveforms 
Doppler waveforms were analyzed at baseline and 90 seconds after cuff deflation. We 
assessed four Doppler parameters: Peak Systolic Velocity (PSV), Acceleration, Percent 
Acceleration Time (%AT), and Pulsatility Index (PI). Percent Acceleration Time is the 
time taken to achieve peak systolic velocity from end diastole. Pulsatility Index is 
defined as (systolic-diastolic velocity)/mean velocity. All values were taken as the 
average of 3 cardiac cycles. (See Figure 2). 

FIGURE 2: Example of Doppler Waveform Data 
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C. Calculation of Pulsatility Index at 90 seconds 
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Fig 2. Illustration of Doppler Measurement of (A) Peak Systolic Velocity, PSV, and 
Acceleration, (B) Acceleration Time, and (C) Pulsatility Index, PI, at 90 seconds post 
cuff deflation. Doppler waveform calculations were obtained from both automatic (C) 
and manual (A and B) caliper measurements and values were taken as an average of 3 
cardiac cycles. 
V. Technique training 
Intensive training in Brachial Artery ultrasound technique was obtained under the 
supervision of Dr. Keith Williams prior to scanning any study participants. One month 
was spent learning the technique, becoming comfortable with the ultrasound machine, 
properly recording data and subsequently doing accurate measurements. During this 
time, approximately 30 ultrasounds were performed on non-pregnant volunteers (friends 
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and staff of the YNHH perinatal unit). Finally, 10 trial ultrasounds were done on patient 
volunteers in both the perinatal unit and the ward. 
C. Data Collection 
Subject data were collected at the time of Ultrasound directly from patients and 
confirmed with subsequent chart review. Lab data were gathered from patient charts. No 
personal identifiers were recorded on the data collection sheets and patients identified by 
study number and initials only. Patient names and assigned study numbers were stored in 
a separate password encrypted file. To view the data collection sheets please refer to 
APPENDIX B. 
D. Measured Outcomes 
The primary outcome is the development of preeclampsia defined as 1) Blood 
pressure increase of >140 mmHg systolic or >90 mmHg diastolic after 20 weeks of 
pregnancy and 2) Proteinuria, defined as 0.3g in a 24hr urine collection or 0.30mg/dl in at 
least 2 random urine specimens. Charts were reviewed for official diagnosis of 
preeclampsia among the participants enrolled in the study. Secondary outcome measures 
include development of early onset or severe preeclampsia, HELLP syndrome, Eclampsia 
(the presence of seizures or coma), placental abruption and gestational hypertension. 
Fetal and neonatal outcomes include intra-uterine growth restriction (IUGR), small for 
gestational age (SGA), fetal demise, apgar scores and neonatal intensive care unit (NICU) 
admission. 
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E. Statistical Analysis 
All data were expressed as mean ± S.D. and 95% confidence interval, when 
appropriate. Student’s t-test was used for comparisons between two groups and ANOVA 
was used for comparisons among three or more groups. Pearson correlation was 
measured using the bivariate correlation model. Sample size calculations are described in 
the participant recruitment section. All other statistical analysis of the data was done 
using SPSS, Version 12.0 statistical package. 
True-positive (TP) was defined as abnormal test results in individuals with 
disease (preeclampsia, adverse pregnancy outcomes); false-positive (FP) as abnormal test 
results in individuals without disease; true-negative (TN) as normal test results in 
individuals without disease; false-negative (FN) as normal test results in individuals with 
disease. Positive Predictive Value (or PPV) was calculated according to the formula of 
TP/(TP+FP) and Negative Predictive Value (or NPV) was calculated as TN/(TN+FN). 
Interobserver agreement was validated by having two investigators, both blinded 
to identity of the subjects, measure the diameters and calculate 15 separate FMVD 
measurements on randomly chosen subjects. The intraclass correlation coefficient was 
0.948 [Cl 0.847-0.982] for N=15, representing a high level of agreement. In other words, 
all values fell within <6% difference between two observers (See Figure 3). 
• ' 
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Figure 3. Interobserver Percent difference 
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Fig. 3 Interobserver agreement demonstrated by examining the percent difference from 
the mean measurement between two observers for 15 measurements of FMVD. The 
intraclass correlation coefficient was 0.948, confirming a high level of agreement 
between two observers. 
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RESULTS 
A. STUDY OVERVIEW: Clinical Characteristics and Demographic Data 
A total of 87 women were enrolled in the study from both YNHH and Trinidad 
(See Table 1). The combined group included 12 Preeclamptic women, 30 Normotensive 
controls and 40 women with pre-existing vascular dysfunction who were at high risk for 
developing preeclampsia. Twelve women from YNHH cohort were enrolled at < 20 
weeks gestational age (minimum=T5.2 weeks). Six of the 12 women had a repeat scan at 
>24 weeks’. In comparison with subjects enrolled from YNHH, women from Trinidad 
were of higher gestational age, lower BMI, more likely to be nulliparous, and were less 
likely to have a history of tobacco use (see Table 2). Each group was a representative 
sample of the community clinic population. 
TABLE 1. Total number of women enrolled, total with complete scans and clinical 
characteristics of women from YNHH, Trinidad and Combined groups. 
Study patients YNHH Trinidad Combined 
Total number enrolled 50 37 87 
Number excluded from analysis A 4 1 5 
Total with complete scan analysis 46 36 82 
• Normotensive Controls 10 20 30 
• Preeclamptic 4 8 12 
• High Risk: Vascular 
D 
Dysfunction 
32 8 40 
A Reasons for exclusion: 2 incomplete scans (less than 5 minutes or 200mmHg cuff 
occlusion), 1 incomplete consent, 1 equipment malfunction, 1 patient carrying twins) 
D 
Women considered to be at high risk for developing preeclampsia had one or more 
preexisting diagnosis; pre-gestational diabetes, insulin-requiring gestational diabetes 
(DMA2), chronic hypertension, gestational hypertension (PIH), previous preeclampsia, 
thromboembolic disease. 
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TABLE 2. Demographic and Clinical Characteristics of women from YNHH and 
Trinidad groups. 
Characteristic YNHH TRINIDAD P Value 
Mean N=50 N=37 
Maternal Age (mean ± S.D.) 29.5 ±6.1 27.7 ±6.1 0.29 
Gestational Age (mean ± S.D.) 26.7 ±6.8 30.1 ±5.8 0.003 
Gravida (mean ± S.D.) 3.88 ±3.9 2.9 ±2.2 0.019 
Nulliparous (n) 6 (12%) 12 (32%) 
BMI (mean ± S.D.) 29.4 ± 9.0 24.4 ±6.1 0.015 
TOTALS 
Ethnicity Black 18 23 41 (47%) 
<»)A Hispanic 16 0 16(18%) 
White 12 0 12 (14%) 
East Indian 0 10 10(11%) 
Other 4 4 8 (9%) 
Smoking Pre Pregnancy 13 (26%) 1 14(16%) 
Status (n)B Current 6(12%) 2 8 (9%) 
A Ethnicity as self identified by patients. East Indian refers to participants of South East 
Asian origin 
D 
Current smokers were asked the time of their last cigarette and none of the subjects in 
the study smoked <4 hours prior to time of experiment. 
B. Specific Aims 1 and 2: Case Control Summary Data 
To compare FMVD in preeclamptic vs. normotensive women we selected 12 
women diagnosed with preeclampsia (4 from YNHH and 8 from Trinidad) and matched 
each to two normotensive controls. Patients were matched 2:1 for gestational age, 
maternal age and ethnicity. Table 3 shows the clinical and demographic characteristics of 
women in the Case Control study. Note that in addition to the matching criteria, there 
was no significant difference in the BMI, the baseline brachial artery diameter and 
*’■, 
-25- 
smoking status of the women. Based on comparison of these characteristics we were 
assured that we had a well matched, diverse case-control sample. 
TABLE 3. Characteristics of Controls and Preeclamptic Women 
Characteristic Controls 
(N=24) 
Preeclamptics 
(#12) 
P Value 
Gestational age weeks (mean ± S.D.) 30.7 ± 5.6 31.7+ 4.7 0.58 
Maternal age years (mean ± S.D.) 28.0+ 6.9 28.3 + 5.2 0.93 
Gravida (mean + S.D.) 
Nulliparous (n) 
2.9 ± 1.8 
7 (29%) 
2.9 ± 2.6 
4 (33%) 
0.95 
BMI 23.4 ± 5.1 26.3 ±9.1 0.22 
Baseline BA diameter (mean ± S.D) 3.65 ±0.40 3.89 ±0.52 0.143 
Systolic BP (mean ± S.D, mm Hg)A 104+14 156+13 <0.0001 
Diastolic BP (mean ± S.D, mm Hg)A 59+11 91 ± 10 <0.0001 
Smokers (n) B 2 (8%) 1 (8%) 
Ethnicity(n) L Black 
White 
East Indian 
Hispanic 
Other 
12 (50%) 
4(17%) 
6 (25%) 
1 
1 
7 (58%) 
2 (17%) 
2 (17%) 
0 
1 
Cases and controls were matched for gestational age, maternal age and ethnicity. 
BA=Brachial artery, diameter measured in millimeters 
A Blood pressure measurements taken prior to brachial artery scan. 
B Current smokers were asked the time of their last cigarette and none of the subjects in 
the study smoked <4 hours prior to time of experiment. 
Ethnicity as self identified by patients. East Indian refers to participants of South East 
Asian origin 
' 
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Table 4 reveals a comparison of FMVD between preeclamptic women and 
normotensive controls measured at 7 time points post cuff deflation. FMVD was 
significantly reduced in women with preeclampsia compared with matched controls at 
each time point after 15seconds. Individual maximum end-diastolic flow mediated 
vascular dilation (FMVD max) represents the best measurement of the difference in 
FMVD between the two groups (4.5% ± 2.7% in preeclamptics vs. 9.8% ± 4.0% in 
controls; p <0.0002). There is a non-significant trend towards an earlier maximum 
FMVD in the preeclamptic group (51 ± 14 seconds) vs. controls (61 ±26 seconds); 
p=0.211. 
The time course for mean FMVD in hyperemic response in the preeclamptic and 
control groups is illustrated in Figure 4. The mean for FMVD does not rise above 3% in 
the preeclamptic group and is below 0 (representing vessel constriction) up to 30 seconds 
post cuff deflation and again at 120 seconds, at the end of the hyperemic response. In the 
control group, we have a normal rise in FMVD after 15 seconds, reaching the peak value 
of 7.1% at the 60-75 second interval. From Table 4 and Figure 4, it is also evident that 
we have a gradual rise to peak mean value between 30 and 75 seconds with wide 
intervals in standard deviation. Looking at individual maximum FMVD values again 
offers the best measurement of brachial artery hyperemic response, both within and 
between groups. 
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TABLE 4. Comparison of mean Flow Mediated Vascular Dilation (FMVD) 
measured at 7 time points post cuff deflation in Preeclamptic and Control group 
Time (s = seconds) Na Mean (%)± SD P value 
FMVD1 0-15s Control 23 -0.8 ± 6.5 0.434 
Preeclamptic 10 -2.6 ± 4.6 
FMVD2 15-30s Control 24 4.7 ±4.6 0.008 
Preeclamptic 11 -0.05 ± 4.5 
FMVD3 30-45s Control 23 6.6 ± 4.6 0.012 
Preeclamptic 11 2.2 ±4.1 
FMVD4 45-60s Control 22 6.4 ± 4.6 0.044 
Preeclamptic 11 2.7 ±4.9 
FMVD5 60-75s Control 24 7.1 ±5.8 0.005 
Preeclamptic 12 1.7 ± 3.1 
FMVD6 75-90s Control 24 4.8 ± 5.4 0.023 
Preeclamptic 12 0.7 ±3.4 
FMVD7 120s + Control 22 3.1 ±4.6 0.002 
Preeclamptic 12 -1.8 ±2.5 
FMVD Max " Control 24 9.8 ±4.0 0.00018 c 
Preeclamptic 12 4.5 ±2.7 
Time Max (s) 
Control 24 61 ±26 
0.211 
Preeclamptic 12 51 ± 14 
A Numbers do not always correspond to 24/12 because a clear image of the lumen was 
not available during the 15 second interval for one or more of the subjects. All subjects 
had at least 5 available scan intervals. 
8 FMVD Max corresponds to maximum FMVD for each patient and Time Max is the 
time point for FMVD Max 
Equal variances assumed. If equal variances not assumed p <0.0001 
■ 
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FIGURE 4. Time course of FMVD in Controls vs. Preeclamptics 
Fig. 4 Timing of reactive hyperemia in Control and Preeclamptic group. FMVD 1-7 
represent percent flow-mediated vascular dilation values at each time point measurement 
from 0 to 120 seconds (s) post cuff release. P values are noted next to individual time 
points. Error bars represent standard deviation; squares and diamonds represent means of 
control and preeclamptic group, respectively. 
One concern for combining preeclamptic patients from YNHH and Trinidad is 
that the combined results for FMVD might mask individual differences between the two 
groups. While diagnostic criteria for preeclampsia are equivalent, management of 
preeclampsia is different. Preeclamptic patients in Trinidad are typically not started on 
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Magnesium Sulfate for seizure prophylaxis and labor is not usually induced pre-term 
unless there are severe complications of preeclampsia. None of the preeclamptics from 
Trinidad in our study were treated with Magnesium Sulfate, while all four from YNHH 
were started on Magnesium Sulfate prior to the study. We compared FMVDmax in 
preeclamptics from YNHH vs. Trinidad to assess for possible differences between the 
two groups. There was no statistical difference in FMVDmax between the two groups 
(3.3% ± 2.6% for YNHH vs. 5.1% ± 2.7% for Trinidad, p=0.308). 
Figure 5 illustrates the distribution of FMVD in Preeclamptic and Control groups. 
While we have a highly significant difference in the means of the two groups (4.5% ± 
2.7% in preeclamptics vs. 9.8% ± 4.0% in controls, p <0.0002), a cut-off value to 
distinguish the two groups could not be set. Several women in the control group outside 
of the 95% Cl had values close to the mean of the preeclamptic group and one of the 
preeclamptic women had max FMVD of >10%. As this was not a longitudinal study, one 
possible explanation for the overlap is that a percentage of women in the Control group 
eventually developed preeclampsia. Since this was a low-risk population, this number is 
not likely to exceed 10% or 2.4 of the 24 controls and would not significantly alter our 
results. 
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Figure 5. Distribution of Max FMVD in Controls and Preeclamptics 
FMVD max 9.8% (S.D. 4.0) 4.5% (S.D. 2.7) 
Time max 61s (S.D. 26) 51s (S.D. 14) 
Fig. 5 Distribution of maximum Flow Mediated Vascular Dilation (FMVD max) values 
in Control and Preeclamptic groups. Individual values are marked as open circles. Bars 
show 95% Confidence Interval (Cl) of the mean. The corresponding time for FMVD 
max in each group is noted as Time max, in seconds (s). 
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C. Specific Aim 3: Waveform Analysis. Is there a correlation? 
We measured four separate Doppler Ultrasound parameters; Acceleration (Acc), 
Peak Systolic Velocity (PSV), percent time spent in Acceleration Phase (%AT) and 
Pulsatility Index (PI). All Doppler waveforms were done before brachial artery occlusion 
and at 90 seconds post cuff deflation and percentage change from baseline in value was 
calculated for each measurement (A). Baseline waveform parameters, prior to brachial 
artery occlusion, were no different between the preeclamptic group and normotensive 
controls (See Table 5). Analysis of percentage change in doppler waveforms at 90 
seconds from baseline in preeclamptic women vs. normotensive controls is shown in 
Table 6. We used all 4 waveform characteristics in the analysis (A PSV, A Acc, A %AT, 
A PI) but found no statistical difference between preeclamptic and normotensive controls 
at 90 seconds. In contrast, FMVD at both 75-90 seconds and at 120 seconds remained 
significant between the two groups (see Table 4). 
TABLE 5. Brachial artery Doppler waveform parameters before occlusion in 
normotensive controls and preeclamptics. 
Waveform Class N A Mean 
Std. 
Deviation P value 
PSV Normal 20 101.53 26.8 0.422 
(cm/s) Preeclamptic 12 93.99 24.7 
Acc Normal 21 1105 282 0.905 
(cm/s2) Preeclamptic 11 1091 329 
%AT Normal 21 13.91 2.5 0.675 
(%) Preeclamptic 12 13.42 3.5 
PI Normal 14 4.19 1.8 0.757 
Preeclamptic 9 4.67 4.3 
A PSV = change in peak systolic velocity, A Acc = change in acceleration, A %AT = 
change in percent acceleration time, A PI = change in Pulsatility Index. A N represents 
the number of subjects with available measurements. 
':. 
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TABLE 5. Percentage change in waveform parameters in normotensive controls 
and preeclamptics at 90 seconds after cuff release. 
Waveform Class Na Mean 
Std. 
Deviation P value 
A PSV 
(%) 
Normal 
Preeclamptic 
20 
12 
13.46 
20.64 
22.70 
27.75 0.432 
A Acc 
(%) 
Normal 
Preeclamptic 
20 
11 
6.92 
12.37 
26.55 
36.45 
0.638 
A % AT 
(%) 
Normal 
Preeclamptic 
20 
12 
-2.49 
2.43 
26.77 
18.60 
0.580 
API 
(%) 
Normal 
Preeclamptic 
11 
9 
-8.35 
18.86 
31.11 
70.66 
0.307 
All measurements were taken at 9C seconds post cuff release and percentage change was 
calculated in reference to baseline values for each parameter. A PSV = change in peak 
systolic velocity, A Acc = change in acceleration, A % AT = change in percent 
acceleration time, A PI = change in Pulsatility Index. A N represents the number of 
subjects with available measurements. 
To verify the normality of value distribution we examined each waveform 
parameter in 75 subjects with available waveform analysis data. Measurements of 
Acceleration, PSV and %AT were available for 75 of the subjects and measurements of 
PI for 60 of the subjects. The mean, standard deviation (S.D.) and distribution of values 
for each waveform characteristic are shown in Figure 6. It can be seen from the 
histograms that there is a large variation around each mean and that the S.D. is greater 
than the mean for each of the four waveform characteristics. Overall, there was 
minimum change from baseline for both %AT and PI (<10% increase) and only a 
moderate change for Acceleration (<15%). However, with a wide distribution around the 
mean, a large number of cases with change of 50% or more were identified. 
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FIGURE 6: Frequency Histograms showing distribution of values for each of the 
Waveform Characteristics: (A) Change in Acceleration, (B) Change in PSV, (C) 
Change in Percent Acceleration, and (D) Change in PI 
6A. Change in Acceleration (AAccel): 6B. Change in Peak Systolic Velocity 
Mean=14.3 ± 28.4% (N=75) (APSV): Mean=26.2 ± 29.9% (N=7S) 
6C. Change in Percent of Acceleration 6D. Change in Pulsatility Index (API): 
Time (AAT): Mean=7.4 ± 22.9% (N=75) Mean = 2.4 ± 50.0% (N=60) 
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Next, we were interested to see if there was a correlation between FMVD and any 
of the Doppler waveform characteristics among the 75 subjects. Table 6 illustrates 
correlation analysis for each waveform characteristic (A Acc, A PSV, A %AT, A PI) as 
compared to FMVD. In our correlation analysis we used values for both FMVD6 (from 
75-90 seconds, mean=86±4 seconds), FMVD7 (at 120 seconds) as well as the average of 
FMVD6/FMVD7 (mean = 103 ± 4 seconds). Although we could not obtain the exact 
value for FMVD at time of Doppler waveform measurement (The ultrasound machine did 
not allow both Doppler waveform and flow assessments to be done simultaneously), the 
average of FMVD6/ FMVD7 likely represents the closest approximation since Doppler 
was measured 90 seconds after cuff deflation and it took approximately 10 seconds to 
obtain correct Doppler measurements. It can be seen from the correlation analysis in 
Table 7 that only APSV significantly correlated with both FMVD7 and average of 
FMVD6/FMVD7 (pierson coefficient 0.223, 0.239, a = 0.04, respectively). To determine 
how well APSV predicted FMVD we used a Scatter plot with linear regression through 
the origin to determine the best fit equation (See Figure 7). Based on the Scatter plot and 
the pierson coefficient values it is evident that APSV at 90 seconds is not strongly 
correlated with FMVD and cannot be used as an accurate independent predictor of 
FMVD. 
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TABLE 7. Correlation between Doppler Waveforms and FMVD in 75 brachial 
artery scans. 
Time post cuff release 
and mean FMVD 
Waveform 
parameter 
N Pierson 
coefficient (p) 
Alpha 
(2-tailed) 
FMVD6 
(tave=86± 4 seconds)B 
A PSV 75 0.227 0.0503 
A Acc 75 0.143 0.222 
Mean=4.31% ± 5.2% A % AT 75 0.121 0.861 
API 60 A -0.170 0.195 
FMVD7 
(t=120 seconds) 
A PSV 75 0.223 0.0441 
A Acc 75 0.043 0.716 
Mean =1.59% ± 4.5% A % AT 75 0.134 0.250 
API 60 A -0.235 0.071 
Average of 
FMVD6/FMVD7 
A PSV 75 0.239 0.0401 
(t.ave=103 ± 4seconds) B A Acc 75 0.097 0.412 
Mean = 2.99% ± 4.5% A % AT 75 0.074 0.532 
API 60 A -0.214 0.104 
A N = 60 for PI, 15 scans did not have Pulsatility Index available. 
D 
t.ave = average time during the specified period for all scans, i.e., t.ave for scans done 
between 75 and 90 seconds was 86± 4 seconds and t.ave for scans between 75 and 120 
seconds was 103 ± 4seconds. 
A PSV = change in peak systolic velocity, A Acc = change in acceleration, A %AT = 
change in percent acceleration time, A PI = change in Pulsatility Index. 
•*:. . . - 1 
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FIGURE 7. Scatter plot of Mean FMVD6/FMVD7 vs. APSV 
Linear Regression through the Origin with 
95.00% Mean Prediction Interval 
Mean(EDD6-7) = 0.07 * ChangePSV 
0.00 50.00 100.00 
Change PSV 
Fig. 7 Graphic representation of the correlation between change in Peak Systolic 
Velocity (PSV) at 90 seconds and FMVD between 75 and 120 seconds (average t =103 ± 
4 seconds). Pierson Correlation=0.239, a=0.04. 
D. Specific Aim 4. High Risk Cohort: Preliminary data from YNHH 
The clinical characteristics of women in the high risk cohort (N=40) for 
developing preeclampsia are summarized in Figure 8. Insulin requiring gestational 
diabetics (DMA2) were included in this group if they had additional risk factors for 
developing preeclampsia (obesity, advanced maternal age >35 (AMA), grandmultipara) 
or had early very elevated glucose values indicating that they were likely previously 
undiagnosed pre-gestational diabetics. Nine of the women in the high risk cohort had 
multiple risk factors for preeclampsia and a complete tally of their risk factors is included 
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in Figure 8. Obesity (defined as pre-gestational BMI >30), while a known high risk 
factor for both vascular dysfunction and preeclampsia, was not included in the selection 
criteria for the high risk cohort. While many women in the high risk cohort were also 
obese they did not carry this diagnosis in the chart and were referred to the high risk 
clinic for other reasons. We did calculate the BMI of all participating subjects and 45% 
of our high risk cohort women were obese with a 10% prevalence of morbid obesity 
(defined as pre-gestational BMI > 40). In contrast, only 13% of normotensive controls 
(low risk) had BMI >30 with no morbidly obese women. 
Risk Factors 
LEGEND 
DM = pre-gestational diabetes 
2+ Risk Factors: 
DMA = gestational diabetes (DMA2) 3 HTN/PIH 
cHTN = chronic hypertension 2 DMA/cHTN 
Prev Pre = previous preeclampsia 1 DMA/PIH 
PIH = gestational hypertension 1 DM/Prev Pre 
DVT = DVT during this pregnancy 1 DM/HTN 
Obesity = defined as BMI >30 
Morbid = morbid obesity, BMI >40 
1 DM/cHTN/PrevPre 
' ' i : 
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At the time of analysis, outcome data were available for 28 of the 32 women in 
the High Risk Cohort at YNHH. Six out of 28 women developed preeclampsia (21%) 
and two women developed gestational hypertension. Severe complications of 
preeclampsia occurred in 3 of the 6 women (see Table 8). These included HELLP 
syndrome, eclampsia, and abruption leading to fetal demise at 29 weeks. In addition to 
preeclampsia other adverse outcomes such as gestational hypertension, abruption and 
intrauterine growth restriction (IUGR) are likely associated with vascular dysfunction. 
Table 9 includes a complete list of adverse pregnancy outcomes in our cohort that were 
likely related to vascular dysfunction. Eleven out of 28 women, or 39% of the cohort, 
had adverse outcomes during their pregnancy. Note that 3 women (11%) suffered fetal 
demise due to either severe preeclampsia, abruption or early gestational hypertension. 
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TABLE 8. Clinical Characteristics and Outcome of High Risk Women who 
Developed Preeclampsia 
High Risk Class GA at 
study A 
GA at 
delivery 
Outcome 
Pre-gestational DM, 
Previous Preeclampsia 
15 and 
24 wks 
29 wks Severe preeclampsia, abruption, IUFD 
Gestational DM 32 wks 41 wks Preeclampsia 
Pre-gestational DM 18 and 
34 wks 
37 wks Preeclampsia 
Pre-gestational DM 18 and 
32 wks 
35 wks Severe preeclampsia and HELLP 
Chronic Hypertension 19 and 
34 wks 
37 wks Post-partum Preeclampsia 
Previous Preeclampsia 24 wks 36 wks PIH, eclampsia 
A GA = gestational age as written in patients’ chart. All scans done under 20 weeks were 
repeated at > 24 weeks. 
TABLE 9. List of Adverse Pregnancy Outcomes A 
Maternal Morbidity Maternal and Fetal Morbidity 
• 3 Preeclampsia • 1 Preeclampsia +abruption + IUFD 
• 1 Preeclampsia/HELLP • 1 PIH + IUFD 
• 1 PIH/Eclampsia • 1 abruption + IUFD 
• 1 abruption/hemorrhage • 1 PIH + IUGR 
• 1 new onset PIH 
A Outcomes unrelated in pathogenesis to underlying vascular dysfunction were not 
included in analysis (i.e. chorioamnionitis, PPROM, PTL) 
IUFD = intrauterine fetal demise. IUGR = intrauterine growth restriction 
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Table 10 shows maximum FMVD based on pregnancy outcome among the 28 
women in the High Risk cohort. Although the mean in the group that developed 
preeclampsia was reduced, it was not significantly lower compared to the women who 
remained normotensive (6.2% ± 5.2% vs. 10.1% ± 5.6%, p=0.152). When the group of 
women who had an adverse pregnancy outcome was compared to the group with a 
favorable pregnancy outcome, the difference in FMVD was highly significant (4.5% ± 
4.2% vs. 11.4% ± 4.9%, p < 0.001, See Table 10). Figure 9 illustrates the distribution of 
maximum FMVD in the adverse and favorable outcome groups. A cut off point of <5% 
in FMVD was selected for the normal FMVD cutoff value (represented by the dotted blue 
line) in Figure 9. This cut off is based on previous values in the literature indicating high 
likelihood of endothelial dysfunction. 
TABLE 10. FMVD max by Pregnancy Outcome 
Outcome group N 
FMVD max 
(%> 
P value 95% Cl 
Mean ± S.D. 
Normotensive A 20 10.06 5.55 Compared with normotensive: I 
Preeclamptic 6 6.18 5.24 0.152 [-1.74, 9.51] 
Favorable Outcome 17 11.39 4.89 Compared with favorable : 
Poor Outcome 11 4.52 4.23 <0.001 [3.27, 10.47] 
A Two women with new onset gestational hypertension (PIH) were excluded from 
analysis. 
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FIGURE 9. Distribution of FMVDmax based on pregnancy outcomes 
Fig 9. Distribution of maximum Flow Mediated Vascular Dilation (FMVD max) in the 
high risk cohort based on adverse pregnancy outcome. Individual values are marked as 
open circles. Bars show 95% Confidence Interval (Cl) of the mean. Dotted Blue line 
represents the selected cut-off point of <5% FMVD. 

-42- 
DISCUSSION 
Endothelial dysfunction is recognized to play a central role in the pathogenesis of 
preeclampsia. We have shown that Brachial Artery Ultrasound is a non-invasive, 
reproducible method for measuring endothelial dysfunction in pregnant women with 
preeclampsia and may have utility in predicting the future development of preeclampsia 
in high risk patients. 
We have demonstrated a significant reduction in flow mediated vascular dilation 
(FMVD) in women with preeclampsia compared with matched controls (4.5% ± 2.7% vs. 
9.8% ± 4.0%; p< 0.002). This reduction is consistent with several other studies in the 
literature (20, 21). However, existing studies using brachial artery ultrasound in pregnant 
women do not use a standardized protocol for inducing brachial artery hyperemia and 
have variable criteria for measuring FMVD. While all studies demonstrate a reduction in 
the preeclamptic group, the mean in reduction is variable. Some of the variation is likely 
due to differences in population and severity of preeclampsia. However, without 
standardized technique and outcome measurements, it is difficult to discern the external 
validity of the studies. 
There needs to be a gold-standard for measuring FMVD as well as for the 
protocol for inducing brachial artery hyperemia. From the review of cardiovascular 
literature using Brachial Artery Ultrasound we have concluded that it is necessary to 
maintain forearm cuff occlusion at > 250mmHg (or at least 50mmHg > systolic pressure) 
for 5 minutes (10, 12, 13, 14, 15). These requirements are outlined in the guidelines set 
■ 
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by the international brachial artery reactivity task force (16) and should be followed in all 
future studies involving pregnant women. 
Standards for optimal measurement of FMVD are more difficult to determine due 
to a change in pattern of hyperemic response of the brachial artery during pregnancy. It 
has been shown in both in-vitro and in-vivo studies that FMVD is enhanced in normal 
pregnancy (18, 25). Measurement of FMVD in the non-pregnant subject is typically 
taken at 60 seconds post cuff release and represents the maximum hyperemic response 
(10, 12, 13, 14, 15). However, by examining the hyperemic response at 15 second 
intervals from 0 to 90 seconds and at 120 seconds, we have shown that there is a wide 
variation in the timing of maximum FMVD (61 ±26 seconds) for normotensive pregnant 
women. Additionally we noted a trend towards earlier timing of maximum FMVD in 
preeclamptic women (51 ± 14 seconds; p=0.211). Takata et al., have also found a 
significant decrease in recovery time for hyperemic response in preeclamptics (13). 
Thus, care should be exercised in the interpretation of FMVD in pregnant women as the 
timing of maximum end-diastolic dilation may vary from patient to patient and subgroups 
with vascular dysfunction (such as preeclamptics). We conclude that individual 
maximum end-diastolic flow mediated dilation (FMVD max) represents the optimal 
measurement of FMVD in pregnant women. 
Overall, our case-control study was superior to previous studies in the literature 
based on several key aspects including optimal study design, protocol and outcome 
measurements. Firstly, preeclamptics were matched 2:1 to normotensive controls based 
on gestational age, maternal age, and ethnicity and had similar BMI, rate of smoking, and 
baseline brachial artery diameter. Secondly, we had a diverse ethnic sample of 
' 
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population from two unique settings. New Haven and Port of Spain, Trinidad. The 
diversity of our sample maximizes the external validity of our study. Thirdly, we 
followed a strict protocol for induction of brachial artery hyperemia that has been 
extensively validated in the cardiovascular literature. Lastly, we used individual 
maximum FMVD for outcome measurement, which represents the optimal measurement 
of FMVD in pregnant women. 
In addition to examining FMVD, we also looked at changes in Doppler waveform 
parameters (peak systolic velocity, acceleration, percent acceleration time, and pulsatility 
index). Correlation between FMVD and change in Doppler waveforms identified only 
the change in Peak Systolic velocity (A PSV) as significant (p=0.040). We did not find a 
difference in A PSV between preeclamptic and normotensive controls. As Doppler 
measurements were taken at 90 seconds, they did not correspond to timing of maximum 
hyperemic response. 
Several investigators have examined various Doppler waveform parameters with 
conflicting results. Chambers et al. found no change in PSV between the previously 
preeclamptic and normotensive group (22). Takata et al. measured PI at maximum 
FMVD and noted a decrease in PI among women with severe Preeclampsia (20). In 
contrast, using a different protocol for inducing hyperemia, Veille et al., have 
demonstrated increase in PI in women who developed Preeclampsia (26). Most recently, 
Williams and Kocer showed a significant increase in PI as well as percent acceleration 
time (%AT) in preeclamptic women (27). Each of the studies varied in respect to 
protocol for inducing hyperemia as well as the time of Doppler measurement. Thus, it is 
difficult to draw any conclusions from the existing literature. Waveform parameters were 
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previously measured by Williams and Kocer at 30-45 seconds after cuff deflation. 
However, since our primary aim was to examine the time course of FMVD and we could 
not simultaneously measure waveform parameters and vessel diameter, we only 
calculated changes in Doppler waveforms at 90 seconds, after the peak of the hyperemic 
response. In future assessments of utility of Doppler ultrasound of the brachial artery 
hyperemic response, Doppler measurements should be appropriately measured earlier 
(prior to 60 seconds), corresponding to the peak of flow mediated vascular dilation. 
In our cohort study, we set out to predict Preeclampsia based on FMVD 
reduction. We enrolled a total of 40 pregnant women in our high risk cohort (32 from 
YNHH and 8 from Trinidad). Pregnancy outcomes were available for 28 of YNHH 
patients at the time of analysis. Outcomes from Trinidad have not been received. Six of 
the 28 women developed preeclampsia (21%), an expected rate among the high-risk 
population in our cohort. Based on the sample size for outcomes to date of 28, the study 
did not have the power to be used in a predictive fashion. Indeed, we did not find a 
significant difference in maximum FMVD among the women who developed 
preeclampsia vs. those who did not. However, this is most likely a reflection of the low 
power due to small sample size (powered at only 33%). Using current means for 
difference in FMVD and S.D., we estimate that to achieve a power of 80% we would 
need 15 women to develop preeclampsia to detect a difference in maximum FMVD. 
Based on 20% average prevalence in our population, this would require a sample size of 
75 high risk patients for our cohort. 
Two studies have examined women at high risk for developing preeclampsia and 
have demonstrated a significant reduction in FMVD in women who developed 
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preeclampsia. The first, by Savvidou et al., enrolled 86 women in London, UK, at 23-25 
weeks’ gestation and looked at development of both IUGR and preeclampsia (23). Both 
women who developed IUGR (n=14) and preeclampsia (n=10) had a significant 
reduction in FMVD (3.58% ± 2.76% for preeclamptics vs. 6.17% ± 2.82 for IUGR vs. 
8.59% ± 2.76% for normal outcome, p<0.0001 and <0.004 respectively). In the second 
study, by Takase et al., 43 high risk women in Saitama, Japan were enrolled during the 
second half of pregnancy (24). These women were high risk for having previous 
Preeclampsia based on either having renal dysfunction, family history of preeclampsia or 
hypertension, primigravity or advanced maternal age. Nine of 43 women (21%) 
developed preeclampsia and had a significant reduction in FMVD, measured at 60 
seconds post cuff deflation (1.6 ± 1.0% vs. 11 ± 4.5%; p<0.05). The authors used at 3% 
cut-off value for FMVD to calculate a 90% positive predictive value (PPV) and 100% 
negative predictive value (NPV) for predicting the development of preeclampsia using 
brachial artery ultrasound technique. 
Our high risk cohort differed from that of Takase et al., for several reasons. Half 
of our cohort had either pre-gestational or gestational diabetes as one risk factor. Our 
mean gestational age was lower than in their study. We had half as many women with 
previous preeclampsia. All of these reasons likely explain why Takase et al., were able to 
show a significant reduction in FMVD in women who subsequently developed 
preeclampsia in a small cohort of 43 women. Additionally, they were working with a 
homogeneous population of Japanese women while we had a diverse ethnic population. 
Differences in brachial artery hyperemic response based on ethnicity have not been 
examined in the literature but may account for a larger variation in FMVD in our cohort. 
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We did not achieve the statistical power to determine a significant difference for 
women who developed preeclampsia in our preliminary analysis. However, we found a 
striking difference in FMVD in a comparison based on adverse pregnancy outcomes. 
Eleven patients in our cohort had adverse pregnancy outcomes likely related to vascular 
dysfunction with three suffering intrauterine fetal demise (IUFD). The reduction in 
FMVD in the group with adverse outcomes (n=l 1) vs. favorable outcomes (n=17) is 
highly significant at a power of 94% (4.52% ± 4.23% vs. 11.39% ± 4.89%; p <0.001). 
Using our previously established cut-off for maximum FMVD of 5%, the PPV of having 
and adverse pregnancy outcome is 90% and the NPV is 84%. No previous studies have 
examined the utility of brachial artery ultrasound in predicting adverse pregnancy 
outcomes related to vascular dysfunction. 
When we examined the two outliers in FMVD values for preeclamptic group 
(FMVD=10.9%, see Fig. 5) and women who developed Preeclampsia in our high risk 
cohort (FMVD= 14.5%, see Fig 9), interestingly, both values were attributed to women 
who also had the HELLP syndrome with preeclampsia. These were the only cases of co¬ 
existing HELLP syndrome among our participants. We did have one preeclamptic 
women develop the HELLP syndrome post-partum, one week after the study and had 
reduced FMVD (2.4%). Fischer et al. examined forearm vascular reactivity in patients 
with Preeclampsia and HELLP syndrome and noted a reduction in vasodilation in the 
Preeclamptic group but no change in the HELLP syndrome and Preeclampsia group as 
compared to normotensive controls (28). Elevated FMVD values in our two 
preeclamptic women with co-existing HELLP syndrome appear to be consistent with 
Fisher’s study results. Additional studies comparing FMVD response in preeclamptic 
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patients with and without the HELLP syndrome are needed to confirm these findings. 
We speculate that different pathogenic mechanisms may underlie the development of the 
HELLP syndrome. 
In the future, we plan to complete our outcome analysis for all 40 subjects 
currently enrolled in our cohort study. We also hope to recruit more patients to the high 
risk cohort to achieve adequate power for the prediction of preeclampsia (a minimum of 
35 additional participants). We would also like to examine Doppler Waveform 
parameters at an earlier time point, prior to maximum FMVD response. The small 
number of patients in our current cohort did not allow us to look at FMVD in specific 
high risk groups, such as diabetics, chronic hypertensives, obese women and women with 
previous preeclampsia. A larger cohort will allow us to examine the degree of 
endothelial dysfunction in specific high risk groups. 
In conclusion, our results support the hypothesis that pregnant women who 
develop preeclampsia have impaired endothelial dysfunction as measured by brachial 
artery ultrasound. Preliminary analysis suggests that the impairment is present prior to 
development of clinical symptoms and brachial artery ultrasound represents a non- 
invasive tool to predict the development of preeclampsia and other adverse outcomes due 
to vascular impairment in high risk populations. Further research is needed to examine 
the degree of underlying endothelial dysfunction during pregnancy in separate high risk 
groups. Based on the literature and our preliminary data, there is strong potential for 
using brachial artery ultrasound to predict the development of preeclampsia and other 
vascular dysfunction related adverse outcomes. Current research using brachial artery 
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ultrasound has illuminated our understanding of the role of endothelial dysfunction in 
pregnancy and more studies applying this technique in pregnancy are necessary. 
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APPENDIX A: 
Advertisements of research study 
1. Flyer content (used at YNHH perinatal unit). 
2. Flyer content (used at Mount Hope Maternity prenatal clinics). 
Note that flyer was modified to include maternal Trans-Cranial 
Doppler Study by Dr. Williams as well as small gift compensation. 
3. Brochure, English version (modified contact info for Trinidad) 
4. Brochure, Spanish version (translation verified by YNHH certified 
Spanish translator). 
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You 
for a prenatal visit? 
Are Invited: 
To participate in a research study on 
high blood pressure during pregnancy 
❖We will do an ultrasound of your arm to look 
at blood flow changes in pregnancy 
❖Ultrasound is safe and presents no risk to 
you or your baby 
❖The session takes about 15 minutes 
❖Please let your health provider know if you 
are interested in participating. 
You can contact us for further questions: 
Inna Landres Keith P. Williams, Mb 
(page) 766-0557 (203)785-3091 

Are you here for a prenatal visit? 
You Are Invited: 
To participate in a research study on 
high blood pressure during pregnancy 
We will do an ultrasound of your arm 
and your head to look at blood flow 
changes in pregnancy 
❖ Ultrasound is safe and presents no risk 
to you or your baby 
❖ The session takes about 30 minutes 
❖ Please let your health provider know if 
you are interested in participating 
To thank you for your time and help you will 
receive a baby gift of your choice. 
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APPENDIX B 
DATA COLLECTION 
1. Participant data collection sheet 
2. Maternal/Perinatal Outcomes data collection sheet 

YALE UNIVERSITY SCHOOL OF MEDICINE 
YALE NEW HAVEN HOSPITAL MEDICAL CENTER 
DATA COLLECTION SHEET 
PREDICTION OF PREECLAMPSIA -STUDY 
DATA ENTERED BY: DATE: 
Study Number Initials 
EGA/EDD 
Date of Birth / / 
Pre-pregnancy weight lbs or kg 
Height ft inches or cm 
Ethnicity HispanicAVhite/Black/Asian/Other 
Cigarette Use No Yes No. Years 
Amt/day pre-preg Amt/day preg 
Alcohol Use No Yes 
Amt/day pre-preg Amt/day preg 
Drug Use No Yes Specify: 
MEDICAL HISTORY 
Check here if NONE 
1. Diabetes Check if yes 
Class: previous 
pregnancy 
current 
pregnancy 
Mother Sisters Other 
A1 = gestational 
A2 - gestational-insulin 
B = < 10 yrs; after 20 y/o 
C= 10-19 yrs; 10-20 y/o 
D = > 20 yrs; before 10 y/o 
F = renal disease 
H = coronary artery disease 
R = retinopathy 
T = renal transplant recipients 
2. Hypertension 
3. Thromboembolic disease 
4. Coagulopathy 
5. Preterm delivery 
6. Preeclampsia 

Check if yes Check if yes 
Medical History In general During this pregnancy 
7. Renal disease 
8. Heart disease 
9. Chron. Hypertension 
10. Thyroid disfunction 
11. Tromboembolic disease 
12. Anemia 
13. sickle cell anemia 
14. Other hemoglobinopathy 
15. Coagulopathy 
16. Pneumonia 
17. SLE/CTD/joint diseases 
18. Drug Sensitivity 
19. Allergies 
20. Blood transfusions 
21. Asthma 
22. Liver, GI disease 
23. Rh incompatibility 
24. Other (specify) 
PAST C OBSTETRIC HISTORY { 
Grav. Term Preterm > 
20wks 
SAB < 20 
wks 
TAB Ectopic Multiples Live Children 
PREVIOUS PREGNANC ES 
Preg. 
# 
GA @ 
delv 
Date / 
Yr 
Birth 
Wt. 
Sex Outcome 
1-7 
Complication 8- 
18 
Placental Pathology 
19-21 
1 
2 
3 
4 
5 
6 
1: Vaginal 
2: forceps 
3: vacuum 
4: c-section 
5: miscarriages 
6: elective termination 
7: med. Indicated 
termination 
8: spontPTL 
placenta 
9: PPROM 
10: PTD for maternal indications 
11: PTD for fetal indications 
12: Preeclampsia 
13: IUFD 
14: IUGR 
15: abruptio 
16: hypertension 
17: diabetes 
18: Other 
19: chorio 
20: abruption 
21: infarcts 

Polyhydramnios/Oligohydramnios _ GA at Dx 
IUGR  GA at Dx 
Preeclampsia _ GA at Dx 
PIH  GA at Dx 
PTL  GA at Dx 
PPROM _ GA at Dx 
GA at Tx 
Gest. DM _ GA at Dx 
diet control  
insulin control_ 
Comment: 
MEDICATIONS 
Check ( 3) if yes 
analgesics _sedatives/anti- depressants 
antibiotics _hormones 
steroids _antifungal medication 
heparin 
LMWH (low molecular weight heparin) started @_wks 
low dose aspirin dose_ 
tocolytics 
_INH/Vit B6 
other 
anti-HTN 
insulin 
anti-asthma 
thyroid-medication 
diet-supplements 
prenatal vitamins/ 
minerals/iron 

Matemal/Perinatal outcome variables: 
Study Number_Initials_ Date 
1. EGA admission to study_wks 
2. Diagnosis 
(may cite more than one) 
PIH 
Preeclampsia 
HELLP 
DM 
Oligohydramnios 
IUGR 
Other (specify) 
3. Complications in labor and delivery 
l=Eclampsia 
3=Acute Renal Failure 
5=HELLP 
7=Matemal pyrexia 
9=vertical incision 
11 ^maternal fits 
13=membranes ruptured >24 hr 
15=cord prolapse 
17=retained placental 
19=Other 
2=DIC 
4=Fetal death 
6=Concealed hemorrhage 
8=Anesthetic accident 
10=rupture of old scar 
12=infected liquor 
14=cord round neck 
16=true knot in cord 
18=placenta previa diagnosed in labor 
Intrapartum care with antihypertensives 
Treatment with MgS04 
Highest uric acid 
Platelet count 
Elevated liver enzymes 
24 hour protein 
Serum Creatinine elevated 
Serum urea elevated 
Hemoglobin 
Hematocrit 
Fibrinogen 

PREGNANCY OUTCOME 
Termination Spontaneous/Elective @ GA _ wks 
If yes: 
Elective Genetic Medically indicated 
reason_ 
Date delivery _/_/_ 
GA at delivery __ weeks_days 
AROM SROM 
Induction Indication 
Mode of delivery: 
Vaginal / Forceps / Vacuum / C-section / 
If operative, what was indication:_ 
Intrapartum Complications 
Temp> 100.4 Abruption Meconium Vag. Bleeding 
Cord Prolapse FHR requiring delivery FHR.160bpm>10mins Antibiotics 
Other 
Placental Pathology ( if available): 
chorioamnionitis 
abruption 
infarcts, vascular pathology 
Placental weight 
Other 
Postpartum Complications 
Anemia PPH Retained Placenta manual removal /curretage 
Systemic Infection UTI Wound Infection CS/Episiotomy 
Other: 

PERINATAL OUTCOME VARIABLES 
Neonatal Outcome 
Check ( 3) if yes 
Baby A Baby B 
Ballard Wks. Ballard Wks 
Birthweight _gram Birthweight _ gram 
Apgar score 1 5 Apgar score 1 5 
Cord PH Cord PH 
Sex Boy / Girl Sex Boy / Girl 
Chartnumber child: Chartnumber child: 
IUFD {intrauterine fetal death) IUFD (intrauterine fetal death) 
Adverse neonatal outcome 
Check ( 3) if yes 
Baby A Baby B Baby C Baby D 
RDS 
TTN 
IVH 
BPD 
NEC 
Hypoglycemia 
Hypocalcemia 
Hyperbilirubinemia 
Sepsis suspected 
Sepsis confirmed 
LBW (< 2500 gr) 
VLBW (< 1500 gr) 
SGA 
LGA 
Demise 
ROP stage/zone 
NICU duration 
NND 
Days of 
Hospitalization 
NICU + step down 

PRENATAL LABS 
TEST RESULTS Date comments 
GC Pos / Neg 
Chlamydia Pos / Neg 
Urine C & S Pos / Neg 
B Strep Pos / Neg 
Creatinine clearance 
(mL / min) 
Urine 24 hrs protein 
(mg/24 hr) 
Hgb (< 20 wks)g/dL 
Hct (< 20 wks) % 
MCV (< 20 wks)fL 
RDW (< 20 wks)% 
AFP(in MOM) 
hCG(in MOM) 
E3(in MOM) 
Folate ng/ml 
B12 pg/mL 
RPR (non) reactive 
HIV NEG/POS 
ADMIT Tests/Labs 
TEST RESULTS Date comments 
BP (range, highest) 
Urine Protein 
Hgb/Hct 
Platelets 
Uric Acid 
BUN/Creatinine 
LDH 
BiliD/BiliT 
AST/ALT 
ALK 
PT/PTT/INR 
Beta Strep 
HIV 
Cultures 
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